An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.
US police have confirmed that Brian Thompson was fatally shot outside an investor conference by a masked assailant.
Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.
Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals to develop BMX-502.
Takeda has signed an agreement to receive an exclusive global licence from Keros Therapeutics for elritercept.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback